Scoop: NIH resets the clock on Xtandi 'march-in' petition request from patients with prostate cancer
First, they heard nothing. Then, the NIH said in January that they would hear something in a month.
But now, that timeline has been extended even further out, perhaps due to the shockwaves that NIH would send to the biopharma industry if it decided to use so-called “march-in” rights to lower the price of a drug that still has patents protecting its monopoly.
The latest correspondence from the NIH’s Office of the Director, which is reviewing this petition and has denied past march-in requests, to Robert Sachs, one of the petitioners and patients with prostate cancer who are seeking to bring down the price of Astellas’ expensive prostate cancer drug Xtandi, shows the NIH hasn’t even really begun its review.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.